PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
September 16, 2025Open Access

Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo

View Full Paper
Ask AI
Bookmark
Share

Authors

IBInderjeet Singh BharajABAjit BrarAKAayushi Kacheria

Discussion

Loading...

Member takes

Overview

This review explores current and emerging therapies for cardiovascular disease and chronic kidney disease, emphasizing innovative treatments and AI integration.

Key Points

  • Emerging therapies show promise in treating cardiovascular-kidney-metabolic syndrome, improving outcomes.
  • Established drugs like SGLT2 inhibitors and GLP-1 receptor agonists reduce cardiovascular events and renal decline.
  • Novel agents targeting specific metabolic pathways are expanding therapeutic options for multifactorial conditions.
  • AI is becoming a key tool in enhancing clinical decision-making for personalized CKM management.

Cite This Study

Bharaj et al. (2025) studied this question.

synapsesocial.com/papers/68d4271f713b0b5dfea6d97fhttps://doi.org/10.20944/preprints202507.0009.v2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Contemporary and Emerging Therapeutics in Cardiovascular-Kidney-Metabolic (CKM) Syndrome: In Memory of Professor Akira Endo2025 · 1 citations
  2. 2Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond2025 · 10 citations
  3. 3From Risk Determinants to Clinical Action2026
  4. 4Cardiovascular-kidney-metabolic-syndrome: a modern view of the problem2025
  5. 5SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular–Kidney–Metabolic Syndrome2025 · 31 citations